Day One Biopharmaceuticals (DAWN)
(Delayed Data from NSDQ)
$6.74 USD
+0.09 (1.28%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $6.73 -0.01 (-0.07%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
DAWN 6.74 +0.09(1.28%)
Will DAWN be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DAWN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DAWN
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 303.46%: Here's is How to Trade
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q1 Loss, Tops Revenue Estimates
DAWN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Jazz Stock Gains as Q4 Earnings & Sales Surpass Expectations
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Tops Revenue Estimates
Perrigo Gears Up to Report Q4 Earnings: Here's What to Expect
Other News for DAWN
Earnings To Watch: Day One Biopharmaceuticals Inc (DAWN) Reports Q2 2025 Result
Franklin Biotechnology Discovery Fund Q2 2025 Commentary
BlackRock, Inc. Reduces Stake in Day One Biopharmaceuticals Inc
AMG TimesSquare Small Cap Growth Fund Q1 2025 Commentary